CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 35.7% in August

Posted by Stanley Muller on Sep 3rd, 2026

CalciMedica Inc. (NASDAQ:CALC – Get Free Report) saw a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 323,241 shares, a drop of 35.7% from the July 30th total of 503,070 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily trading volume, of 320,704 shares, the short-interest ratio is currently 1.0 days.

CalciMedica Stock Up 5.0%

CalciMedica stock opened at $2.10 on Thursday. The firm has a market cap of $14.34 million, a price-to-earnings ratio of -0.31 and a beta of 0.83. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. CalciMedica has a fifty-two week low of $2.00 and a fifty-two week high of $36.00. The firm has a fifty day moving average price of $3.65 and a two-hundred day moving average price of $3.48.

CalciMedica (NASDAQ:CALC – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. As a group, analysts forecast that CalciMedica will post -5.25 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on CALC. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Guggenheim began coverage on shares of CalciMedica in a research note on Thursday, August 20th. They set a “buy” rating on the stock. UBS Group restated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Finally, Wall Street Zen raised shares of CalciMedica to a “sell” rating in a research note on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $50.00.

Get Our Latest Report on CalciMedica

Insider Buying and Selling at CalciMedica

In related news, Director Fred A. Middleton purchased 49,794 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were acquired at an average cost of $4.00 per share, with a total value of $199,176.00. Following the completion of the purchase, the director owned 212,654 shares of the company’s stock, valued at $850,616. The trade was a 30.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 28.25% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC increased its position in CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after acquiring an additional 39,775 shares during the period. 180 Wealth Advisors LLC increased its holdings in CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after buying an additional 94,650 shares during the period. Boothbay Fund Management LLC bought a new stake in CalciMedica in the fourth quarter valued at about $506,000. Jane Street Group LLC bought a new position in shares of CalciMedica during the fourth quarter valued at $127,000. Finally, Cetera Investment Advisers raised its stake in shares of CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares during the last quarter.

About CalciMedica

(Get Free Report)

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.